Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Jia Q, Bielefeldt-Ohmann H, Masleša-Galić S, Bowen RA, Horwitz MA. Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters.[...]
Sandigo-Saballos I, Montero S, Lee P, Lee H, Chen KT. Less is More: A Cost and Environmental Waste Analysis in Nonadherence to Antibiotic Prophylaxis Guidelines[...]
Ertem Z, Danesharasteh A, Anand ST, Jackson NJ, Nelson RE, Schechter-Perkins EM, Fisher L, Doron S, Branch-Elliman W. Impact of lifting school mask mandates on[...]